| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Lgals7 |
| Uniprot No | P47929 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-136aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFSNVPHKSSLPEGIRPGTVLRI RGLVPPNASRFHVNLLCGEEQGSDAALHFNPRLDTSEVVFNSKEQGSWGR EERGPGVPFQRGQPFEVLIIASDDGFKAVVGDAQYHHFRHRLPLARVRLV EVGGDVQLDSVRIF |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Lgals7(Galectin-7)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant Galectin-7 Induces Apoptosis in T Lymphocytes Through Phosphatidylserine Exposure"*
**作者**：Kashio et al.
**摘要**：研究通过原核系统表达重组Galectin-7.发现其能通过诱导细胞膜磷脂酰丝氨酸外翻触发T淋巴细胞凋亡，提示其在免疫调控中的作用。
2. **文献名称**：*"Structural and Functional Analysis of Recombinant Galectin-7: Role of Dimerization in Carbohydrate Binding"*
**作者**：Leppänen et al.
**摘要**：解析重组Galectin-7的晶体结构，证明其二聚体形式对结合β-半乳糖苷类配体至关重要，并揭示其结合位点突变对功能的影响。
3. **文献名称**：*"Galectin-7 Recombinant Protein Suppresses Tumor Growth via Modulating Autophagy in Squamous Cell Carcinoma"*
**作者**：Chen et al.
**摘要**：利用哺乳动物细胞表达系统制备功能性重组Galectin-7.发现其通过激活自噬通路抑制鳞状细胞癌模型中的肿瘤生长。
---
以上研究均聚焦于重组Lgals7的表达制备及其在细胞凋亡、结构功能或肿瘤治疗中的机制探索。如需扩展，建议在PubMed或Web of Science中结合关键词**"recombinant Galectin-7"**或**"Lgals7 protein purification"**进一步检索。
**Background of LGALS7 Recombinant Protein**
LGALS7. also known as galectin-7. is a member of the galectin family of β-galactoside-binding proteins. It is encoded by the *LGALS7* gene and is characterized by a conserved carbohydrate recognition domain (CRD) that mediates interactions with glycoproteins and glycolipids. Galectin-7 is a small, approximately 15 kDa protein, typically functioning as a homodimer. It is primarily expressed in epithelial tissues, including the skin, thymus, and gastrointestinal tract, and plays roles in cell-cell adhesion, apoptosis, and immune regulation.
Recombinant LGALS7 protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification to ensure high specificity and activity. Its recombinant form enables researchers to study its biological functions *in vitro* and *in vivo* without interference from endogenous proteins. Studies have shown that galectin-7 is involved in diverse physiological and pathological processes. For instance, it acts as a pro-apoptotic agent in damaged epithelial cells, contributes to tissue repair, and modulates inflammatory responses. However, its dual role in cancer—acting as either a tumor suppressor or promoter depending on the context—has garnered significant interest. Elevated galectin-7 expression is observed in certain cancers, such as melanoma and lymphoma, where it may influence tumor progression, immune evasion, or metastasis.
Research on LGALS7 recombinant protein also extends to its potential as a therapeutic target or diagnostic biomarker. Its interaction with immune cells, such as T cells and dendritic cells, highlights its relevance in autoimmune diseases and immunotherapy. Overall, LGALS7 recombinant protein serves as a critical tool for deciphering the complex roles of galectin-7 in health and disease.
×
